Free Trial

Sanofi (SNY) Competitors

Sanofi logo
$48.61 -0.73 (-1.48%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$48.40 -0.20 (-0.42%)
As of 07/11/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SNY vs. NVO, NVS, AZN, GSK, TAK, ARGX, BNTX, ONC, TEVA, and INSM

Should you be buying Sanofi stock or one of its competitors? The main competitors of Sanofi include Novo Nordisk A/S (NVO), Novartis (NVS), AstraZeneca (AZN), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BioNTech (BNTX), BeOne Medicines (ONC), Teva Pharmaceutical Industries (TEVA), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

Sanofi vs. Its Competitors

Sanofi (NASDAQ:SNY) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.3%. Novo Nordisk A/S pays an annual dividend of $1.64 per share and has a dividend yield of 2.4%. Sanofi pays out 57.1% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 48.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novo Nordisk A/S has lower revenue, but higher earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanofi$44.46B2.68$6.02B$2.8017.36
Novo Nordisk A/S$42.12B7.31$14.64B$3.3820.39

Sanofi presently has a consensus target price of $61.50, suggesting a potential upside of 26.52%. Novo Nordisk A/S has a consensus target price of $112.00, suggesting a potential upside of 62.48%. Given Novo Nordisk A/S's higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sanofi
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
3 Strong Buy rating(s)
3.11
Novo Nordisk A/S
2 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.27

In the previous week, Sanofi had 4 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 46 mentions for Sanofi and 42 mentions for Novo Nordisk A/S. Novo Nordisk A/S's average media sentiment score of 1.16 beat Sanofi's score of 0.84 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sanofi
18 Very Positive mention(s)
6 Positive mention(s)
9 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
Novo Nordisk A/S
33 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Novo Nordisk A/S has a net margin of 34.52% compared to Sanofi's net margin of 14.56%. Novo Nordisk A/S's return on equity of 80.94% beat Sanofi's return on equity.

Company Net Margins Return on Equity Return on Assets
Sanofi14.56% 17.15% 9.80%
Novo Nordisk A/S 34.52%80.94%24.23%

Sanofi has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Summary

Novo Nordisk A/S beats Sanofi on 11 of the 19 factors compared between the two stocks.

Get Sanofi News Delivered to You Automatically

Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SNY vs. The Competition

MetricSanofiLarge Cap Pharma IndustryMedical SectorNASDAQ Exchange
Market Cap$119.21B$254.33B$5.56B$9.11B
Dividend Yield3.29%2.83%5.06%4.01%
P/E Ratio17.3627.9128.2620.26
Price / Sales2.685.00437.10166.10
Price / Cash9.1213.9337.1257.67
Price / Book1.4617.848.045.49
Net Income$6.02B$8.49B$3.19B$250.45M
7 Day Performance-0.56%0.73%3.62%4.79%
1 Month Performance-2.13%-2.20%5.98%9.59%
1 Year Performance-5.30%-5.29%29.39%16.41%

Sanofi Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SNY
Sanofi
4.14 of 5 stars
$48.61
-1.5%
$61.50
+26.5%
-5.3%$119.21B$44.46B17.3682,878Trending News
Analyst Revision
NVO
Novo Nordisk A/S
4.633 of 5 stars
$69.31
+0.2%
$112.00
+61.6%
-51.5%$309.47B$42.12B20.5177,349Positive News
NVS
Novartis
1.5475 of 5 stars
$122.11
+0.2%
$123.67
+1.3%
+8.3%$257.95B$50.32B19.0875,883Upcoming Earnings
AZN
AstraZeneca
3.7594 of 5 stars
$69.63
+0.3%
$85.00
+22.1%
-10.2%$215.94B$54.07B27.9694,300Positive News
Analyst Forecast
GSK
GSK
1.7895 of 5 stars
$38.21
+0.1%
$37.38
-2.2%
-2.2%$78.23B$40.10B19.7068,629Gap Down
TAK
Takeda Pharmaceutical
2.1186 of 5 stars
$15.07
-1.8%
N/A+9.2%$47.95B$30.09B68.5047,455Positive News
ARGX
argenex
4.4131 of 5 stars
$546.04
+0.5%
$728.06
+33.3%
+20.1%$33.34B$2.25B33.691,599Analyst Upgrade
BNTX
BioNTech
1.6374 of 5 stars
$110.05
+0.0%
$137.86
+25.3%
+32.9%$26.45B$2.98B-32.376,772News Coverage
Analyst Forecast
ONC
BeOne Medicines
3.4372 of 5 stars
$240.99
-1.8%
$320.67
+33.1%
N/A$26.41B$4.18B-64.7811,000Trending News
Analyst Downgrade
Insider Trade
TEVA
Teva Pharmaceutical Industries
4.1226 of 5 stars
$16.84
-1.0%
$24.13
+43.3%
-5.2%$19.31B$16.54B-14.6436,830
INSM
Insmed
4.3703 of 5 stars
$96.95
-0.9%
$106.80
+10.2%
+28.0%$18.39B$363.71M-16.291,271Positive News
Analyst Forecast
Insider Trade

Related Companies and Tools


This page (NASDAQ:SNY) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners